Low-dose tirzepatide cuts HbA1c 1.5% in Japanese real-world cohort

The wire

1. 01The multicenter retrospective ESTATE study followed 88 Japanese adults with type 2 diabetes on an average 4.5 mg weekly tirzepatide dose for 24 weeks; HbA1c fell 1.5% and BMI 1.5 kg/m2, both p<0.001.
2. 02Albumin rose while ALT and LDL cholesterol fell, and higher baseline HbA1c predicted greater reduction, relevant to clinicians using sub-maximal doses.
3. 03Authors note causal inference is limited by the single-arm observational design and absence of a control group; patient-reported outcome analyses were exploratory.

From the source

Real-world effectiveness and safety of low-dose tirzepatide in Japanese people with type 2 diabetes: a multicenter, retrospective, single-arm, observational study-East Shizuoka Tirzepatide (ESTATE) study

Endocrine journal · 2026 Sep 29 · Iwamoto T, Yamasaki N, Nojiri S et al.